| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 41899 |
Unlisted procedure, dentoalveolar structures |
752 |
663 |
$1.48M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
24,879 |
19,923 |
$1.09M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
26,338 |
23,285 |
$995K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
7,029 |
5,906 |
$335K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
3,530 |
3,376 |
$326K |
| 80053 |
Comprehensive metabolic panel |
20,301 |
18,589 |
$189K |
| 87631 |
|
1,117 |
1,089 |
$115K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
24,480 |
22,136 |
$106K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,190 |
3,907 |
$79K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,797 |
1,978 |
$70K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,607 |
1,471 |
$51K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,760 |
2,522 |
$50K |
| 81001 |
|
9,490 |
8,926 |
$36K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
607 |
594 |
$35K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,611 |
2,389 |
$27K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
561 |
542 |
$25K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
561 |
542 |
$25K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
449 |
393 |
$24K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
179 |
166 |
$22K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
528 |
485 |
$18K |
| 70450 |
Computed tomography, head or brain; without contrast material |
185 |
178 |
$14K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
384 |
366 |
$13K |
| 87081 |
|
1,523 |
1,496 |
$13K |
| 71046 |
Radiologic examination, chest; 2 views |
877 |
838 |
$12K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
94 |
91 |
$10K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
348 |
324 |
$9K |
| 84703 |
|
828 |
790 |
$7K |
| 84443 |
Thyroid stimulating hormone (TSH) |
549 |
529 |
$7K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
108 |
86 |
$7K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
219 |
83 |
$6K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
291 |
282 |
$6K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
512 |
491 |
$5K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
338 |
330 |
$5K |
| 83690 |
|
692 |
640 |
$5K |
| 84484 |
|
501 |
442 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
25,329 |
22,277 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
190 |
154 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
405 |
386 |
$4K |
| 86780 |
|
197 |
195 |
$4K |
| G0378 |
Hospital observation service, per hour |
58 |
40 |
$3K |
| 87070 |
|
387 |
378 |
$3K |
| J3490 |
Unclassified drugs |
4,230 |
2,817 |
$3K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
74 |
70 |
$3K |
| 80061 |
Lipid panel |
237 |
237 |
$3K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
95 |
95 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
127 |
118 |
$2K |
| 83874 |
|
231 |
210 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
90 |
43 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
241 |
226 |
$2K |
| 99070 |
|
564 |
515 |
$2K |
| 87205 |
|
330 |
323 |
$2K |
| 88142 |
|
80 |
78 |
$2K |
| 86803 |
|
96 |
96 |
$2K |
| 83605 |
|
196 |
182 |
$2K |
| 97597 |
|
22 |
13 |
$2K |
| 96376 |
|
106 |
89 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
172 |
170 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
44 |
42 |
$2K |
| 87186 |
|
123 |
119 |
$1K |
| 85610 |
|
508 |
380 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
126 |
119 |
$1K |
| 87430 |
|
113 |
112 |
$1K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
12 |
12 |
$1K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
43 |
43 |
$1K |
| 83735 |
|
237 |
218 |
$1K |
| 93971 |
|
13 |
12 |
$1K |
| 84439 |
|
93 |
92 |
$965.02 |
| 87340 |
|
64 |
64 |
$954.34 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
66 |
30 |
$783.10 |
| 73630 |
|
40 |
40 |
$744.60 |
| 86850 |
|
78 |
78 |
$716.51 |
| 82962 |
|
148 |
95 |
$715.96 |
| 83655 |
|
48 |
47 |
$707.59 |
| 87088 |
|
61 |
61 |
$703.11 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
14 |
13 |
$702.49 |
| 84702 |
|
64 |
53 |
$694.08 |
| 97161 |
|
18 |
18 |
$660.70 |
| 87077 |
|
63 |
62 |
$659.37 |
| 82728 |
|
34 |
33 |
$587.40 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
28 |
25 |
$583.11 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,588 |
3,371 |
$565.82 |
| 81025 |
|
70 |
66 |
$555.69 |
| 73130 |
|
30 |
29 |
$529.19 |
| 86901 |
|
82 |
80 |
$521.59 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,254 |
1,126 |
$469.22 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
48 |
48 |
$441.04 |
| 73562 |
|
29 |
28 |
$431.83 |
| 86900 |
|
82 |
80 |
$413.47 |
| 82607 |
|
28 |
28 |
$400.08 |
| 86140 |
|
59 |
52 |
$390.10 |
| 86762 |
|
41 |
41 |
$377.99 |
| J2704 |
Injection, propofol, 10 mg |
1,288 |
1,087 |
$369.69 |
| 85379 |
|
48 |
46 |
$347.38 |
| 87040 |
|
32 |
31 |
$341.47 |
| 82570 |
|
58 |
51 |
$322.09 |
| 0001A |
|
52 |
51 |
$318.30 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
647 |
568 |
$297.23 |
| 0002A |
|
49 |
49 |
$289.72 |
| 85652 |
|
58 |
50 |
$282.84 |
| 84145 |
|
13 |
13 |
$274.63 |
| 73110 |
|
15 |
15 |
$274.61 |
| 72100 |
|
16 |
16 |
$265.76 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
32 |
31 |
$258.15 |
| 82951 |
|
13 |
12 |
$255.59 |
| 85027 |
|
29 |
29 |
$242.45 |
| 73610 |
|
15 |
15 |
$231.70 |
| 81003 |
|
161 |
152 |
$190.24 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
83 |
70 |
$186.41 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
21 |
17 |
$181.23 |
| 0011A |
|
20 |
19 |
$173.16 |
| 83550 |
|
16 |
16 |
$171.41 |
| 0012A |
|
16 |
16 |
$144.58 |
| 82950 |
|
19 |
19 |
$143.92 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
180 |
166 |
$142.45 |
| 83540 |
|
29 |
29 |
$133.11 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,042 |
1,013 |
$116.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
614 |
553 |
$102.79 |
| 84550 |
|
14 |
14 |
$80.20 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
28 |
27 |
$68.29 |
| 80164 |
|
15 |
12 |
$62.96 |
| J2060 |
Injection, lorazepam, 2 mg |
54 |
40 |
$59.37 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
44 |
39 |
$43.63 |
| 82077 |
|
94 |
84 |
$31.08 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
16 |
16 |
$22.34 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
12 |
12 |
$16.69 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
56 |
55 |
$0.72 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
39 |
37 |
$0.12 |
| C1773 |
Retrieval device, insertable (used to retrieve fractured medical devices) |
82 |
79 |
$0.00 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
27 |
27 |
$0.00 |
| 36416 |
|
26 |
24 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
13 |
12 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
206 |
202 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
14 |
14 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
43 |
39 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
44 |
40 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
17 |
17 |
$0.00 |